Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Aprotinin (BPTI): Mechanistic Insights for Blood Management
2026-05-27
Explore how Aprotinin, a bovine pancreatic trypsin inhibitor, advances blood management research by combining precise serine protease inhibition with new mechanistic insights from membrane biophysics. This article bridges molecular action with emergent applications in perioperative and cardiovascular settings.
-
Acifran: Structural Selectivity and Assay Innovation in Lipi
2026-05-27
Explore how Acifran, a selective (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is transforming lipid metabolism research through structural selectivity insights and practical assay optimization. This article delivers a fresh, in-depth analysis of Acifran's molecular interactions, bridging cryo-EM findings to actionable scientific workflows.
-
Refining In Vitro Drug Response Metrics in Cancer Research
2026-05-26
Schwartz's dissertation introduces a more nuanced framework for evaluating anti-cancer drug responses in vitro by distinguishing between proliferative arrest and cell death. This approach clarifies the interpretation of apoptosis inhibitor effects and guides more predictive preclinical study designs.
-
AT-406 (SM-406): Advanced Insights into IAP Antagonism and A
2026-05-26
Explore how AT-406 (SM-406) uniquely targets inhibitor of apoptosis proteins, enabling precise apoptosis pathway activation in cancer cells. This article offers a deeper protocol-based perspective and integrates the latest structural biology findings for optimal research design.
-
(S)-(+)-Ibuprofen: Precision COX Inhibitor for Lab Research
2026-05-25
(S)-(+)-Ibuprofen from APExBIO sets a new standard in selective COX inhibition, empowering researchers to dissect inflammation and pain pathways with high reproducibility. Discover advanced experimental workflows, troubleshooting strategies, and unique insights from recent toxicology studies to maximize your assay success.
-
SU 5402 in Cancer & Neuronal Models: Protocols and Pitfalls
2026-05-25
SU 5402 stands out as a multi-targeted receptor tyrosine kinase inhibitor, enabling high-precision dissection of FGFR, VEGFR, and PDGFR pathways in cancer biology and neuronal disease research. This article details hands-on workflows, troubleshooting guidance, and strategic protocol enhancements for robust use in experimental models, highlighting nuanced insights from recent advances.
-
Gefitinib (ZD1839): Enhancing EGFR Pathway Research in Assem
2026-05-24
Gefitinib (ZD1839) empowers cancer researchers to dissect EGFR signaling and drug resistance in patient-derived assembloid models that closely mimic tumor complexity. Its nanomolar potency and proven performance in advanced co-culture systems enable more predictive, physiologically relevant drug testing.
-
Catalpol Reduces Depressive-like Behaviors via NLRP3 Pathway
2026-05-23
This study demonstrates that Catalpol alleviates depressive-like behaviors in a chronic unpredictable mild stress (CUMS) mouse model by targeting oxidative stress-mediated activation of the NLRP3 inflammasome and neuroinflammation. The findings provide mechanistic insight into Catalpol's neuroprotective and anti-inflammatory actions, with practical implications for translational depression research.
-
Protease Inhibitor Cocktail: Precision in Protein Extraction
2026-05-22
The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) from APExBIO sets a new standard for preserving protein integrity during extraction, especially in workflows sensitive to divalent cations. Its compatibility with advanced applications like phosphorylation analysis and kinase assays distinguishes it from conventional protease inhibitors.
-
Moxifloxacin as a Research Probe: Decoding DNA Gyrase and Be
2026-05-22
Discover how Moxifloxacin, a leading fluoroquinolone antibiotic, enables advanced mechanistic studies of DNA gyrase inhibition, cellular proliferation, and metabolic responses. This article uniquely explores its use as a research probe, offering fresh scientific and assay design insights.
-
Adiponectin Mitigates Cognitive Deficits via TLR4/NF-κB Inhi
2026-05-21
This study demonstrates that adiponectin alleviates splenectomy-induced cognitive dysfunction in aged rats by suppressing neuroinflammation and oxidative stress through the TLR4/MyD88/NF-κB pathway. The findings advance mechanistic understanding of perioperative neurocognitive disorder, highlighting new avenues for intervention and translational research.
-
Gramine Triggers Ferroptosis in TNBC via CUL3–MTDH Ubiquitin
2026-05-21
The referenced study establishes that gramine, a natural indole alkaloid, suppresses triple-negative breast cancer by inducing ferroptosis through a CUL3–MTDH axis. This mechanistic insight highlights gramine's unique regulatory effects on ferroptosis and underscores the value of robust cell viability assays for evaluating anti-cancer strategies.
-
Targeted Amikacin Delivery via Dendritic Cells in Granulomas
2026-05-20
This study demonstrates the feasibility of using dendritic cells as cellular vehicles for localized delivery of Amikacin into granulomas in Mycobacterium avium-infected mice. The approach offers a promising strategy to enhance antibiotic efficacy against non-tuberculous mycobacterial infections while minimizing systemic toxicity and resistance development.
-
RNA Pol II Inhibition Triggers Apoptosis Independently of Tr
2026-05-20
Harper et al. (2025) reveal that cell death following RNA polymerase II inhibition is not due to passive mRNA decay, but is instead a regulated, apoptosis-driven response initiated by the loss of hypophosphorylated RNA Pol IIA. These insights reshape our understanding of cell death mechanisms in cancer research and suggest new avenues for targeting apoptosis pathways.
-
Tamoxifen in Breast Cancer Research: Mechanisms, Innovations
2026-05-19
Explore the multifaceted role of Tamoxifen as a selective estrogen receptor modulator in breast cancer research, with a deep dive into its mechanistic innovations and advanced uses in gene knockout models. This article provides unique assay insights and bridges recent findings on caveolin-1 modulation.